[go: up one dir, main page]

BE2013C071I2 - - Google Patents

Download PDF

Info

Publication number
BE2013C071I2
BE2013C071I2 BE2013C071C BE2013C071C BE2013C071I2 BE 2013C071 I2 BE2013C071 I2 BE 2013C071I2 BE 2013C071 C BE2013C071 C BE 2013C071C BE 2013C071 C BE2013C071 C BE 2013C071C BE 2013C071 I2 BE2013C071 I2 BE 2013C071I2
Authority
BE
Belgium
Application number
BE2013C071C
Original Assignee
Genentech Inc
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35517336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2013C071(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Curis Inc filed Critical Genentech Inc
Publication of BE2013C071I2 publication Critical patent/BE2013C071I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/141—Esters of phosphorous acids
    • C07F9/142—Esters of phosphorous acids with hydroxyalkyl compounds without further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
BE2013C071C 2004-09-02 2013-12-04 BE2013C071I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60736704P 2004-09-02 2004-09-02

Publications (1)

Publication Number Publication Date
BE2013C071I2 true BE2013C071I2 (fr) 2024-10-09

Family

ID=35517336

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2013C071C BE2013C071I2 (fr) 2004-09-02 2013-12-04

Country Status (26)

Country Link
US (8) US7888364B2 (fr)
EP (1) EP1789390B1 (fr)
JP (3) JP5143558B2 (fr)
KR (13) KR20180122750A (fr)
CN (2) CN101072755A (fr)
AT (1) ATE532768T1 (fr)
AU (3) AU2005282722C1 (fr)
BE (1) BE2013C071I2 (fr)
BR (1) BRPI0514841B1 (fr)
CA (1) CA2579002C (fr)
CY (2) CY1112630T1 (fr)
DK (1) DK1789390T3 (fr)
EA (3) EA201100604A1 (fr)
ES (1) ES2377430T3 (fr)
HU (1) HUS1300068I1 (fr)
IL (2) IL181673A (fr)
LU (1) LU92278I2 (fr)
MX (1) MX2007002584A (fr)
NO (1) NO339260B1 (fr)
NZ (1) NZ589385A (fr)
PL (1) PL1789390T3 (fr)
PT (1) PT1789390E (fr)
SI (1) SI1789390T1 (fr)
UA (1) UA96565C2 (fr)
WO (1) WO2006028958A2 (fr)
ZA (1) ZA200702537B (fr)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1399163B1 (fr) * 2001-01-13 2007-10-10 University Of North Carolina At Chapel Hill Composes, procedes et compositions servant au traitement de l'infection par le virus de la diarrhee bovine virale (vbvd) et l'infection par le virus de l'hepatite c (vhc)
KR20180122750A (ko) 2004-09-02 2018-11-13 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
AU2005287729A1 (en) 2004-09-22 2006-03-30 H. Lundbeck A/S 2-acylaminothiazole derivatives
US7674912B2 (en) 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
DE602006010546D1 (de) * 2005-06-16 2009-12-31 Pfizer N-(pyridin-2-yl)sulfonamidderivate
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
CA2650653C (fr) 2006-04-28 2016-03-29 Momenta Pharmaceuticals, Inc. Procedes d'evaluation de l'acetate de glatiramere
UA93548C2 (uk) * 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
AU2008224941C1 (en) 2007-03-14 2013-06-27 Exelixis Patent Company Llc Inhibitors of the hedgehog pathway
EP2137162B1 (fr) 2007-03-15 2018-08-01 Novartis AG Composés organiques et leurs utilisations
PE20090236A1 (es) 2007-04-06 2009-03-13 Neurocrine Biosciences Inc Antagonistas de los receptores de la hormona liberadora de gonadotropina y procedimientos relacionados con ellos
JP5735799B2 (ja) 2007-04-06 2015-06-17 ニューロクライン バイオサイエンシーズ，インコーポレイテッド ゴナドトロピン放出ホルモン受容体拮抗薬およびそれに関連する方法
EP2136803B1 (fr) 2007-04-18 2012-05-02 Merck Sharp & Dohme Corp. Dérivés de triazole qui sont des antagonistes de smo
JP5373777B2 (ja) * 2007-06-07 2013-12-18 アイアールエム・リミテッド・ライアビリティ・カンパニー ヘッジホッグ経路モジュレーターとしてのビフェニルカルボキサミド誘導体
ES2422285T3 (es) 2007-08-16 2013-09-10 Irm Llc Métodos y composiciones para tratar cánceres
TW200918521A (en) * 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
UY31322A1 (es) * 2007-09-05 2009-04-30 Amidas heterocíclicas y sus métodos de uso-975
ES2392157T3 (es) 2007-09-07 2012-12-05 Amgen Inc. Piridazinas anilladas para el tratamiento de tumores dirigidos por señalización Hedgehog inapropiada
DE102007042754A1 (de) * 2007-09-07 2009-03-12 Bayer Healthcare Ag Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
EP2195312B1 (fr) 2007-10-09 2012-11-21 Merck Patent GmbH Dérivés de pyridine utiles comme activateurs de glucokinase
GB0725214D0 (en) * 2007-12-24 2008-02-06 Karobio Ab Pharmaceutical compounds
CN101917853B (zh) 2007-12-27 2014-03-19 无限药品股份有限公司 立体选择性还原的方法
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US20090281089A1 (en) * 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
NZ588001A (en) * 2008-04-29 2012-06-29 Lilly Co Eli Disubstituted phthalazine hedgehog pathway antagonists
WO2009154739A2 (fr) * 2008-06-17 2009-12-23 Duke University Modulateurs du récepteur smoothened
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
EA018721B1 (ru) 2008-08-25 2013-10-30 Айрм Ллк Модуляторы сигнального пути hedgehog
EP3023097A1 (fr) * 2008-10-01 2016-05-25 Novartis AG Antagonisme lissé pour le traitement de troubles liés à la voie hedgehog
PT2364185E (pt) * 2008-11-03 2013-07-24 Lilly Co Eli Ftalazina dissubstituída antagonista da via hedgehog
WO2010056620A1 (fr) 2008-11-17 2010-05-20 Eli Lilly And Company Pyridazines tétrasubstituées antagonistes de la voie hedgehog
PL2358698T3 (pl) 2008-11-17 2013-01-31 Lilly Co Eli Czteropodstawione pirydazyny jako antagoniści szlaku HEDGEHOG
CN102223797A (zh) 2008-11-21 2011-10-19 高点制药有限责任公司 金刚烷基苯甲酰胺化合物
US8748623B2 (en) 2009-02-17 2014-06-10 Syntrix Biosystems, Inc. Pyridinecarboxamides as CXCR2 modulators
EP2233566A1 (fr) 2009-03-17 2010-09-29 Vrije Universiteit Brussel Génération de cellules souches pancréatiques
FR2943669B1 (fr) * 2009-03-24 2011-05-06 Sanofi Aventis Derives de nicotinamide,leur preparation et leur application en therapeutique
WO2010144586A1 (fr) 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Dérivés de l'isoquinoléine, de la quinoléine et de la quinazoléine servant d'inhibiteurs de signal hedgehog
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
FR2948367A1 (fr) 2009-07-24 2011-01-28 Centre Nat Rech Scient Derives d'acyl-guanidines modulateurs de la voie de signalisation des proteines hedgehog
WO2011014888A1 (fr) * 2009-07-31 2011-02-03 Selexagen Therapeutics Inhibiteurs inédits de la voie de signalisation hedgehog
CA2769795C (fr) 2009-08-05 2020-01-07 Infinity Pharmaceuticals, Inc. Transamination enzymatique d'analogues de cyclopamine
AU2011204370B2 (en) 2010-01-07 2015-03-05 Selexagen Therapeutics, Inc. Hedgehog inhibitors
ES2593256T3 (es) 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
US8722731B2 (en) 2010-06-07 2014-05-13 Novomedix, Llc Furanyl compounds and the use thereof
WO2012015715A1 (fr) 2010-07-27 2012-02-02 High Point Pharmaceuticals, Llc Dérivés de thiazol-2-ylamine substitués, compositions pharmaceutiques et procédés d'utilisation en tant que modulateurs de 11-bêta-hsd1
CA2811990C (fr) * 2010-08-23 2023-03-21 Dean Y. Maeda Aminopyridinecarboxamides et aminopyrimidinecarboxamides utilisables en tant que modulateurs des recepteurs cxcr2
WO2012037217A1 (fr) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Hydrogénation par transfert d'analogues de cyclopamine
FR2965263A1 (fr) * 2010-09-24 2012-03-30 Sanofi Aventis Derives de thienopyridine nicotinamide, leur preparation et leur application en therapeutique
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
FR2967498B1 (fr) 2010-11-16 2015-01-02 Centre Nat Rech Scient Utilisation de derives de quinolinone comme outil de recherche
EP2468726B1 (fr) 2010-12-06 2013-08-28 Siena Biotech S.p.A. Composant pour le traitement des tumeurs et métastases de tumeurs
TWI574687B (zh) * 2011-01-03 2017-03-21 古利斯股份有限公司 具有鋅結合部份之刺蝟拮抗劑
US9708299B2 (en) 2011-01-03 2017-07-18 Genentech, Inc. Hedgehog antagonists having zinc binding moieties
EP3581574A1 (fr) 2011-01-10 2019-12-18 Infinity Pharmaceuticals, Inc. Composition pour administration orale à utiliser dans le traitement du cancer, d'une maladie inflammatoire ou d'une maladie auto-immune
AP2014007400A0 (en) 2011-07-13 2014-01-31 Novartis Ag 4-Piperidinyl compounds for use as tankyrase inhibitors
JP2014520860A (ja) 2011-07-13 2014-08-25 ノバルティス アーゲー タンキラーゼ阻害剤として使用するための４−オキソ−３，５，７，８−テトラヒドロ−４Ｈ−ピラノ｛４，３−ｄ｝ピルミニジニル化合物
US9181266B2 (en) 2011-07-13 2015-11-10 Novartis Ag 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
JP6027611B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
FR2980477B1 (fr) 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
CA2860676A1 (fr) 2012-01-09 2013-07-18 Novartis Ag Compositions organiques pour traiter des maladies associees a la beta-catenine
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN103570625A (zh) * 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
CN102731373B (zh) * 2012-07-19 2013-11-27 南京药石药物研发有限公司 抗肿瘤药物gdc-0449中间体的制备方法
US9512106B2 (en) 2012-09-17 2016-12-06 Duke University Smoothened modulators and methods of use thereof
NZ708563A (en) 2012-11-01 2019-02-22 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
CN105101959B (zh) * 2012-11-05 2018-04-17 南特知识产权控股有限责任公司 作为刺猬信号传导通路的抑制剂的含有环状磺酰胺的衍生物
WO2014085523A1 (fr) 2012-11-29 2014-06-05 Strasspharma Llc Procédés de modulation de l'activité de l'hormone folliculo-stimulante
CN103910672B (zh) * 2013-01-08 2016-10-05 连云港润众制药有限公司 Vismodegib的制备方法
CN103910671B (zh) * 2013-01-08 2016-08-10 正大天晴药业集团股份有限公司 Vismodegib及其中间体的制备方法
CN103040824B (zh) * 2013-01-17 2015-05-27 四川大学 信号通路抑制剂及其制备方法和用途
HUE039052T2 (hu) 2013-02-19 2018-12-28 Novartis Ag Benzotiofénszármazékok és azok készítményei szelektív ösztrogén receptor lebontóként
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014147504A2 (fr) 2013-03-22 2014-09-25 Shilpa Medicare Limited Procédé de préparation de formes solides de 2-chloro-n-(4-chloro-3-(pyridin-2-ylphényl)-4-méthylsulfonylbenzamide
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
CN103254124A (zh) * 2013-04-23 2013-08-21 镇江圣安医药有限公司 N-[4-氯-3–(吡啶-2-基)苯基]-2-氯-4–(甲磺酰基)-苯甲酰胺衍生物及其应用
WO2014194254A1 (fr) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Traitement anticancer au moyen de modulateurs isoformes de la kinase p13
WO2014195977A2 (fr) * 2013-06-05 2014-12-11 Hetero Research Foundation Nouveaux polymorphes de vismodegib
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
WO2015051241A1 (fr) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
EP3964507A1 (fr) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015092634A1 (fr) 2013-12-16 2015-06-25 Novartis Ag Composés et compositions de 1,2,3,4-tétrahydroisoquinoléine en tant qu'antagonistes et agents de dégradation sélectifs des récepteurs des œstrogènes
EP3094627B1 (fr) 2014-01-17 2018-08-22 Novartis AG Dérivés de 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine et compositions les contenant pour l'inhibition de l'activité de shp2
WO2015107494A1 (fr) 2014-01-17 2015-07-23 Novartis Ag Dérivés de 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine et compositions les contenant pour l'inhibition de l'activité de shp2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
JP6701088B2 (ja) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物
CN106458974B (zh) * 2014-03-24 2019-07-16 广东众生药业股份有限公司 作为smo抑制剂的喹啉衍生物
WO2015160986A2 (fr) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Polythérapies
WO2015168079A1 (fr) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Dérivés de pyrimidine ou de pyridine utiles en tant qu'inhibiteurs de pi3k
WO2015169269A1 (fr) 2014-05-05 2015-11-12 Zentiva, K.S. Sels de 2-chloro-n- (4-chloro -3- (pyridin -2-yl)phényl)-4- (méthylsulfonyl)benzamide
WO2015170218A1 (fr) 2014-05-07 2015-11-12 Pfizer Inc. Inhibiteurs de kinases apparentées à la tropomyosine
CA2955570A1 (fr) * 2014-08-07 2016-02-11 Basf Se Cristaux multicomposants de vismodegib et agents de formation de co-cristaux ou solvants selectionnes
RU2718914C2 (ru) 2014-09-13 2020-04-15 Новартис Аг Сочетанные способы лечения с использованием ингибиторов alk
WO2016054491A1 (fr) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
CA2963281A1 (fr) 2014-10-03 2016-04-07 Novartis Ag Polytherapies
CN104496889A (zh) * 2014-11-20 2015-04-08 成都平和安康医药科技有限公司 一种工业化合成维莫地尼的方法
EP3233918A1 (fr) 2014-12-19 2017-10-25 Novartis AG Polythérapies
US9765050B2 (en) * 2014-12-30 2017-09-19 Novira Therapeutics, Inc. Pyridyl reverse sulfonamides for HBV treatment
US10189813B2 (en) 2015-03-25 2019-01-29 Novartis Ag Formylated N-heterocyclic derivatives as FGFR4 inhibitors
CA2988289C (fr) 2015-06-04 2023-12-05 PellePharm, Inc. Formulations topiques pour l'administration de composes inhibiteurs du herisson et leur utilisation
CA2987067A1 (fr) * 2015-06-05 2016-12-08 Dana-Farber Cancer Institute, Inc. Composes et methodes de traitement du cancer
EP3310774B1 (fr) 2015-06-19 2020-04-29 Novartis AG Composés et compositions pour l'inhibition de l'activité de shp2
WO2016203404A1 (fr) 2015-06-19 2016-12-22 Novartis Ag Composés et compositions pour inhiber l'activité de shp2
WO2016203405A1 (fr) 2015-06-19 2016-12-22 Novartis Ag Composés et compositions pour inhiber l'activité de shp2
CN104926714B (zh) * 2015-07-02 2017-07-28 天津大学 2‑氯‑n‑(4‑氯‑3‑(2‑吡啶基)苯基)‑4‑甲基砜苯基苯甲酰胺的制备方法
WO2017050224A1 (fr) * 2015-09-21 2017-03-30 广东众生药业股份有限公司 Forme saline et forme cristalline d'un dérivé de quinoléine, procédé de préparation et intermédiaire de celui-ci
CN105524056A (zh) * 2016-01-05 2016-04-27 中山大学肿瘤防治中心 一种氨基噻唑化合物及其制备方法和应用
US20170231968A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
EA201892075A1 (ru) 2016-03-15 2019-04-30 Оризон Дженомикс, С.А. Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
WO2017191599A1 (fr) 2016-05-04 2017-11-09 Genoscience Pharma Dérivés substitués de 2, 4-diamino-quinoléine pour leur utilisation dans le traitement de maladies prolifératives
WO2017214269A1 (fr) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
US10934285B2 (en) 2016-06-14 2021-03-02 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
BR112018077021A2 (pt) 2016-06-24 2019-04-02 Infinity Pharmaceuticals, Inc. terapias de combinação
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
WO2018049214A1 (fr) 2016-09-09 2018-03-15 Incyte Corporation Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
WO2018049191A1 (fr) 2016-09-09 2018-03-15 Incyte Corporation Dérivés de pyrazolopyridone en tant que modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
ES2927104T3 (es) 2016-09-09 2022-11-02 Incyte Corp Derivados de pirazolopiridina como moduladores de HPK1 y usos de los mismos para el tratamiento del cáncer
US10548908B2 (en) * 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
CN110099900B (zh) * 2016-12-27 2022-12-02 山东大学 针对Smoothened突变株的刺猬通路抑制剂
WO2018133114A1 (fr) * 2017-01-23 2018-07-26 Shenzhen University Nouvel algicide naturel à faible toxicité vis-à-vis d'organismes non ciblés
WO2018152220A1 (fr) 2017-02-15 2018-08-23 Incyte Corporation Composés de pyrazolopyridine et leurs utilisations
CN106892863B (zh) * 2017-03-09 2019-06-11 山东大学 维莫德吉及其中间体的制备方法
GB2560903A (en) 2017-03-27 2018-10-03 Azad Pharmaceutical Ingredients Ag New synthetic path to pharmaceutically acceptable vismodegib
CN107200708B (zh) * 2017-05-27 2020-03-20 新发药业有限公司 一种维莫德吉的制备方法
CN107556289A (zh) * 2017-06-22 2018-01-09 天津国际生物医药联合研究院 一种氯苯‑吡啶类化合物及其应用
GB201713784D0 (en) * 2017-08-29 2017-10-11 E-Therapeutics Plc Modulators of hedgehog (Hh) Signalling pathway
WO2019051199A1 (fr) 2017-09-08 2019-03-14 Incyte Corporation Composés de 6-cyano-indazole utilisés en tant que modulateurs de kinase 1 progénitrices hématopoïétiques (hpk1)
EP3681879A1 (fr) 2017-09-11 2020-07-22 Krouzon Pharmaceuticals, Inc. Inhibiteurs allostériques octahydrocyclopenta[c]pyrrole de shp2
WO2019152711A1 (fr) 2018-01-31 2019-08-08 Diciphera Pharmaceuticals Llc. Polythérapie pour le traitement de tumeurs stromales gastro-intestinales
WO2019152719A1 (fr) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Polythérapie pour le traitement de la mastocytose
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
LT3755703T (lt) 2018-02-20 2022-10-10 Incyte Corporation N-(fenil)-2-(fenil)pirimidin-4-karboksamido dariniai ir susiję junginiai, kaip hpk1 inhibitoriai, skirti vėžio gydymui
WO2019164847A1 (fr) 2018-02-20 2019-08-29 Incyte Corporation Composés d'indazole et leurs utilisations
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
CN113164419A (zh) 2018-09-07 2021-07-23 皮克医疗公司 Eif4e抑制剂和其用途
WO2020061101A1 (fr) 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Dérivés hétéroaryles tri-substitués utilisés en tant qu'inhibiteurs de la phosphatase src à homologie-2
US11111247B2 (en) 2018-09-25 2021-09-07 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
CA3113241A1 (fr) 2018-09-25 2020-04-02 Black Diamond Therapeutics, Inc. Derives de quinazoline utilises en tant qu'inhibiteur de tyrosine kinase, compositions, leurs procedes de preparation et leur utilisation
WO2020068873A1 (fr) 2018-09-25 2020-04-02 Black Diamond Therapeutics, Inc. Compositions d'inhibiteur de tyrosine kinase, procédés de fabrication et procédés d'utilisation
CN112839715B (zh) 2018-09-29 2024-12-03 诺华股份有限公司 抑制shp2活性化合物的制造方法
WO2020072540A1 (fr) * 2018-10-03 2020-04-09 Nantbio, Inc. Inhibiteur double de voies de transduction de signaux sonic hedgehog et wnt/bêta-caténine
EP3643713A1 (fr) * 2018-10-23 2020-04-29 iOmx Therapeutics AG Inhibiteurs de kinase hétérocycliques et leurs utilisations
US11795160B2 (en) 2019-02-22 2023-10-24 Insilico Medicine Ip Limited Kinase inhibitors
US20220040207A1 (en) * 2019-04-02 2022-02-10 The University Of Chicago Remodilins to prevent or treat cancer metastasis, glaucoma, and hypoxia
CR20220097A (es) 2019-08-06 2022-06-01 Incyte Corp Formas sólidas de un inhibidor de hpk1
WO2021030405A1 (fr) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib pour le traitement de tumeurs stromales gastro-intestinales
CA3150433A1 (fr) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib pour le traitement de tumeurs stromales gastro-intestinales
WO2021030711A1 (fr) 2019-08-15 2021-02-18 Black Diamond Therapeutics, Inc. Composés d'alcynyle quinazoline
FI4084779T3 (fi) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
FI4084778T3 (fi) 2019-12-30 2023-12-18 Deciphera Pharmaceuticals Llc Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi
BR112022017727A2 (pt) 2020-03-03 2022-11-16 Pic Therapeutics Inc Inibidores de eif4e e usos dos mesmos
WO2021195206A1 (fr) 2020-03-24 2021-09-30 Black Diamond Therapeutics, Inc. Formes polymorphes et utilisations associées
EP4173639A4 (fr) 2020-06-26 2024-03-13 RaQualia Pharma Inc. Méthode de sélection d'un patient cancéreux pour lequel une polythérapie d'un rétinoïde et d'un agent de traitement du cancer sera efficace, et médicament combiné d'un rétinoïde et d'un agent de traitement du cancer
EP4204020A1 (fr) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Méthode de traitement de cancers exprimant le psma
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
WO2022043556A1 (fr) 2020-08-31 2022-03-03 Novartis Ag Composition pharmaceutique stable
KR20230107568A (ko) 2020-10-13 2023-07-17 엔데버 바이오메디신스, 인크. 섬유증 치료 방법
CA3202355A1 (fr) 2020-12-22 2022-06-30 Jiping Fu Composes pour la degradation de la kinase 2 dependante des cyclines par l'intermediaire d'une voie de l'ubiquitine-proteosome
MX2023008296A (es) 2021-01-13 2023-09-29 Monte Rosa Therapeutics Inc Compuestos de isoindolinona.
WO2022170052A1 (fr) 2021-02-05 2022-08-11 Black Diamond Therapeutics, Inc. Dérivés de quinazoline, dérivés de pyridopyrimidine, dérivés de pyrimidopyrimidine et leurs utilisations
WO2022211811A1 (fr) 2021-03-31 2022-10-06 Genentech, Inc. Vismodegib en association avec un adénovirus de type 5 à réplication déficiente pour l'expression de l'interféron gamma pour le traitement du cancer de la peau
EP4323349A1 (fr) 2021-04-14 2024-02-21 Monte Rosa Therapeutics AG Composés amide d'isoindolinone utilisés pour traiter des maladies associées à gspt1
EP4323350A1 (fr) 2021-04-14 2024-02-21 Monte Rosa Therapeutics AG Composés d'iso-indolinone
TW202317589A (zh) 2021-07-14 2023-05-01 美商尼坎醫療公司 作為ｋｒａｓ抑制劑的伸烷基衍生物
JP2024532276A (ja) 2021-08-25 2024-09-05 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用
EP4392422A1 (fr) 2021-08-25 2024-07-03 PIC Therapeutics, Inc. Inhibiteurs d'eif4e et leurs utilisations
GB202201283D0 (en) * 2022-02-01 2022-03-16 Omass Therapeutics Ltd Pharmaceutical compounds
WO2023168298A2 (fr) * 2022-03-02 2023-09-07 Denali Therapeutics Inc. Composés, compositions et procédés
AU2023243322A1 (en) 2022-03-28 2024-10-03 Nikang Therapeutics, Inc. Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
EP4504705A1 (fr) 2022-04-05 2025-02-12 Synthon B.V. Formes solides de vismodégib
WO2023240024A1 (fr) 2022-06-08 2023-12-14 Nikang Therapeutics, Inc. Dérivés de sulfamide utilisés en tant qu'inhibiteurs de kinase 2 dépendant de la cycline
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
WO2024102849A1 (fr) 2022-11-11 2024-05-16 Nikang Therapeutics, Inc. Composés bifonctionnels contenant des dérivés de pyrimidine 2,5-substitués pour dégrader la kinase 2 dépendante des cyclines par l'intermédiaire d'une voie ubiquitine-protéasome

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0167491A3 (fr) * 1984-07-06 1986-12-30 Ciba-Geigy Ag Dérivés d'acide thiobarbiturique
JPH0813741B2 (ja) 1987-08-10 1996-02-14 協和醗酵工業株式会社 抗痴呆剤
JPH02196721A (ja) * 1989-01-24 1990-08-03 Green Cross Corp:The 抗癌剤
DE4323916A1 (de) 1993-07-16 1995-01-19 Basf Ag Substituierte 2-Phenylpyridine
US5631206A (en) * 1993-10-06 1997-05-20 E. I. Du Pont De Nemours And Company Herbicidal heteroaryl substituted anilides
DE19500758A1 (de) 1995-01-13 1996-07-18 Basf Ag Substituierte 2-Phenylpyridine
TR199700749T1 (xx) * 1995-02-02 1998-02-21 Smithkline Beecham P.L.C. 5-HT resept�r antagonisti olarak indole t�revleri.
WO1997003967A1 (fr) * 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Composes aromatiques substitues et leur utilisation pharmaceutique
WO2001019800A2 (fr) * 1999-09-16 2001-03-22 Curis, Inc. Mediateurs de voies de signalisation hedgehog, preparations et utilisations associees
FR2801305B1 (fr) * 1999-11-24 2002-12-06 Galderma Res & Dev Analogues de la vitamine d
US7115653B2 (en) * 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
US6683192B2 (en) 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
US6645990B2 (en) * 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
CN1429199A (zh) * 2000-10-17 2003-07-09 纳幕尔杜邦公司 杀虫剂1,8－萘二甲酰胺
JP4083422B2 (ja) * 2000-12-22 2008-04-30 石原産業株式会社 アニリン誘導体またはその塩ならびにそれらを含有するサイトカイン産生抑制剤
CN1289072C (zh) 2000-12-22 2006-12-13 石原产业株式会社 苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂
US7687664B2 (en) 2001-06-04 2010-03-30 Eisai R&D Management Co., Ltd. Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it
NZ530580A (en) 2001-07-27 2007-02-23 Curis Inc Mediators of hedgehog signaling pathways, compositions and uses related thereto
JP2005504084A (ja) * 2001-09-21 2005-02-10 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺虫性ジアミド
GB0124932D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124928D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
ATE455104T1 (de) * 2001-11-01 2010-01-15 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
WO2003051876A1 (fr) 2001-12-14 2003-06-26 Japan Tobacco Inc. Derives de pyrazolopyridine et son utilisation medicinale
JP4361800B2 (ja) 2001-12-21 2009-11-11 サイトキネティックス， インコーポレイテッド 心不全を処置するための組成物および方法
AU2003245700A1 (en) * 2002-02-12 2003-09-04 Glaxo Group Limited Pyrazolopyridine derivatives
CN100369898C (zh) * 2002-02-12 2008-02-20 史密丝克莱恩比彻姆公司 用作p38抑制剂的烟酰胺衍生物
JP2006511583A (ja) * 2002-12-20 2006-04-06 ファルマシア・コーポレーション マイトジェン活性化プロテインキナーゼ−活性化プロテインキナーゼ−２を阻害するための非環式ピラゾール化合物
US8067608B2 (en) * 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
WO2005040152A1 (fr) 2003-10-20 2005-05-06 E.I. Dupont De Nemours And Company Azolecarboxamides substitues par heterocyclylphenyle et heterocyclylpyridile
WO2005085227A1 (fr) 2004-03-02 2005-09-15 Smithkline Beecham Corporation Inhibiteurs de l'activite de la proteine kinase b (akt)
US7880000B2 (en) * 2004-05-07 2011-02-01 Amgen Inc. Protein kinase modulators and method of use
KR20180122750A (ko) * 2004-09-02 2018-11-13 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling

Also Published As

Publication number Publication date
CY2013042I2 (el) 2015-12-09
CN101072755A (zh) 2007-11-14
BRPI0514841A (pt) 2008-06-24
WO2006028958A2 (fr) 2006-03-16
KR20200118909A (ko) 2020-10-16
KR20150002863A (ko) 2015-01-07
KR20160058972A (ko) 2016-05-25
KR20070085243A (ko) 2007-08-27
WO2006028958A3 (fr) 2006-04-13
KR20150090263A (ko) 2015-08-05
EA017262B1 (ru) 2012-11-30
US9278961B2 (en) 2016-03-08
CA2579002C (fr) 2012-11-27
US20110092461A1 (en) 2011-04-21
EP1789390A2 (fr) 2007-05-30
JP2008511675A (ja) 2008-04-17
CY2013042I1 (el) 2015-12-09
EP1789390B1 (fr) 2011-11-09
KR20210090744A (ko) 2021-07-20
US20060063779A1 (en) 2006-03-23
PT1789390E (pt) 2012-02-08
IL214451A0 (en) 2011-09-27
MX2007002584A (es) 2007-09-07
EA201100604A1 (ru) 2014-06-30
KR20190072678A (ko) 2019-06-25
UA96565C2 (ru) 2011-11-25
JP5143558B2 (ja) 2013-02-13
KR20130083488A (ko) 2013-07-22
KR20170001725A (ko) 2017-01-04
US9790183B2 (en) 2017-10-17
KR20180122750A (ko) 2018-11-13
US20240116872A1 (en) 2024-04-11
AU2005282722A1 (en) 2006-03-16
JP2014148537A (ja) 2014-08-21
JP2012184255A (ja) 2012-09-27
KR101225018B1 (ko) 2013-01-23
KR101366414B1 (ko) 2014-03-18
US20180029984A1 (en) 2018-02-01
ES2377430T3 (es) 2012-03-27
BRPI0514841B1 (pt) 2021-10-26
CA2579002A1 (fr) 2006-03-16
IL181673A (en) 2013-12-31
SI1789390T1 (sl) 2012-05-31
KR20200019263A (ko) 2020-02-21
LU92278I9 (fr) 2019-03-06
US20210070707A1 (en) 2021-03-11
PL1789390T3 (pl) 2012-04-30
AU2011201229A1 (en) 2011-04-14
EA200700538A1 (ru) 2007-10-26
AU2005282722B2 (en) 2011-03-03
LU92278I2 (fr) 2013-11-11
KR20120139846A (ko) 2012-12-27
ZA200702537B (en) 2008-08-27
NO339260B1 (no) 2016-11-21
US20200010420A1 (en) 2020-01-09
DK1789390T3 (da) 2012-02-27
US9321761B2 (en) 2016-04-26
ATE532768T1 (de) 2011-11-15
US7888364B2 (en) 2011-02-15
NZ589385A (en) 2011-03-31
KR20140048343A (ko) 2014-04-23
AU2023237067A1 (en) 2023-10-12
EA201890903A1 (ru) 2019-02-28
NO20071719L (no) 2007-05-31
HUS1300068I1 (hu) 2019-03-28
US20150105550A1 (en) 2015-04-16
AU2005282722C1 (en) 2011-08-18
US20160152569A1 (en) 2016-06-02
CY1112630T1 (el) 2015-12-09
IL181673A0 (en) 2007-07-04
CN102964294A (zh) 2013-03-13
EA201890903A9 (ru) 2021-11-10

Similar Documents

Publication Publication Date Title
BE2024C508I2 (fr)
BE2024C511I2 (fr)
BE2022C549I2 (fr)
BE2023C542I2 (fr)
BE2021C001I2 (fr)
BE2020C513I2 (fr)
BE2020C517I2 (fr)
BE2019C540I2 (fr)
BE2019C548I2 (fr)
BE2018C045I2 (fr)
BE2017C063I2 (fr)
BE2017C027I2 (fr)
BE2017C023I2 (fr)
BE2017C002I2 (fr)
BE2020C525I2 (fr)
BE2016C067I2 (fr)
BE2016C014I2 (fr)
BE2015C063I2 (fr)
BE2015C041I2 (fr)
BE2015C038I2 (fr)
BE2015C066I2 (fr)
BE2014C010I2 (fr)
BE2013C071I2 (fr)
BE2013C021I2 (fr)
BE2012C025I2 (fr)